In jacketed glass-lined reactors of 0.5–2.0 m³ working volume, N-carbobenzoxy-L-alanine is activated through mixed carboxylic-carbonic anhydride formation with isobutyl chloroformate and N-methylmorpholine in tetrahydrofuran at -20 °C to -10 °C. The exothermic activation is controlled by jacket circulation at -25 °C and by limiting isobutyl chloroformate addition to 0.3–0.5 L/min per 100 kg of Cbz-L-alanine; deviation above -8 °C increases the urethane by-product and reduces coupling selectivity by 4–7% according to HPLC area-normalized pilot-scale records. The mixed anhydride is coupled to a C-terminal amino acid ester hydrochloride, charged at 1.00–1.15 molar equivalents of Cbz-L-alanine relative to the amine nucleophile, with 1.10–1.30 molar equivalents of N-methylmorpholine and 1.00–1.10 molar equivalents of isobutyl chloroformate. The coupling is maintained at -5 °C to 0 °C for 2–4 h, followed by aqueous work-up with 0.5 M citric acid at pH 6.5–7.0 to avoid pH-induced oxazolone formation. The Cbz-protected dipeptide is crystallized from ethyl acetate/n-heptane; unreacted Cbz-L-alanine and N-acylurea side products are rejected to mother liquors. Deprotection is conducted in a hydrogenation autoclave with 5% Pd/C (10% wet basis) in methanol at 0.3–0.5 MPa hydrogen and 25 ± 2 °C. The observed batch-to-batch failure mode is catalyst poisoning by sulfur-containing impurities traced to residual thionyl chloride from C-terminal ester synthesis; sulfate ash must be below 0.05% before hydrogenation. Residual palladium is reduced to <10 µg/g by activated carbon treatment and filtration through a 0.45 µm membrane. The released peptide API intermediate is controlled by HPLC purity ≥99.5 area% and single unknown impurity ≤0.10 area%. Compliance for this route follows ICH Q7 Sections 5, 8, and 12, with residual solvents controlled under ICH Q3C and elemental impurities under ICH Q3D; analytical release uses USP <467> and USP <233>. Terminal product types include oligopeptide APIs, peptide drug substance intermediates, and pharmacopeial peptide monographs.

Why Does Cbz-L-alanine Survive Mixed Anhydride Route Design in Enalapril-Type ACE Inhibitor Synthesis?

Because Cbz-L-alanine suppresses the formation of diketopiperazine by keeping the amino group blocked until the dipeptide backbone is fully assembled, it remains the preferred N-protected L-alanine synthon in enalapril-type synthesis. The route couples Cbz-L-alanine to L-proline methyl ester hydrochloride in tetrahydrofuran at -20 °C to -15 °C using isobutyl chloroformate and N-methylmorpholine; the charge ratio is 1.00–1.05 molar equivalents of Cbz-L-alanine, 1.00–1.05 molar equivalents of isobutyl chloroformate, and 1.00–1.10 molar equivalents of N-methylmorpholine relative to the proline ester. The reaction mixture is held for 1–2 h at -15 °C and then quenched with 0.5 M citric acid. The isolated Cbz-Ala-Pro-OMe is crystallized from ethyl acetate/n-heptane; the crystallizer is equipped with a temperature ramp from 50 °C to 0 °C at 0.5 °C/min to remove the minor R-epimer. Hydrogenolysis over 5% Pd/C in ethanol at 0.3 MPa and 25 ± 2 °C removes the Cbz group, and the deprotected alanyl-proline methyl ester is condensed with ethyl 2-oxo-4-phenylbutyrate under reductive amination conditions. The final API is controlled under the USP and Ph. Eur. monographs for enalapril maleate; compliance during intermediate manufacturing follows ICH Q7 Section 12, ICH Q11, and ICH Q3C. Finished product testing is anchored to FDA 21 CFR 211.165. Terminal product types include ACE inhibitor APIs in tablet and sterile injectable forms, where the peptide intermediate is converted to the maleate salt and milled to a particle-size distribution of D90 ≤ 50 µm before formulation. Operational boundaries: Cbz-L-alanine should not be exposed to strong secondary amines at pH > 8.5, because benzyl carbamate aminolysis forms benzyl amine adducts and reduces yield; for this reason, triethylamine substitution for N-methylmorpholine is avoided.

Because short-chain cosmetic peptides including palmitoyl dipeptides and tripeptide-1 analogs are assembled by solution-phase coupling when cost constraints exclude resin-based Fmoc manufacturing, Cbz-L-alanine is introduced as the protected alanine building block at 1.0–1.2 molar equivalents relative to the C-terminal amino acid benzyl or methyl ester. The coupling is run in N,N-dimethylformamide or dichloromethane at 0–5 °C with N,N'-diisopropylcarbodiimide and 1-hydroxybenzotriazole; the addition rate of the coupling reagent is adjusted to maintain the internal temperature below 5 °C, because local exotherms above 8 °C produce measurable racemization at the alanine α-carbon. After Cbz removal by catalytic hydrogenolysis with 5% Pd/C in ethanol/water at 0.2–0.4 MPa, the intermediate is N-acylated with palmitoyl chloride at pH 8.0–8.5 in a water/tetrahydrofuran mixture. The final cosmetic peptide active is purified on a preparative reversed-phase HPLC column with C18 bonded silica, eluting with acetonitrile/water containing 0.1% trifluoroacetic acid, and lyophilized to a water content below 5%. Compliance for the cosmetic peptide active follows EC 1223/2009 Annex II for restricted substances, ISO 22716 for manufacturing hygiene, and REACH (EC) No 1907/2006; residual palladium is controlled to <10 µg/g and benzyl alcohol to <100 ppm. In finished cosmetic formulations, the peptide active is typically added at 1–10 ppm (0.0001–0.001 wt%) in anti-aging serums, eye contour creams, and skin barrier repair emulsions. Published data for the exact formulation addition window of Cbz-L-alanine-derived cosmetic peptides in commercial cosmetic matrices is limited, so the synthetic ratio is anchored to the upstream coupling rather than to the final cosmetic dosage.

Analytical Release and Storage Specifications for Cbz-L-alanine in Custom Peptide CRO Operations

In custom peptide CRO and CDMO operations, Cbz-L-alanine is maintained as a chiral building block of ≥99.0% enantiomeric excess by chiral HPLC and ≥99.0% assay by titration or qNMR. The material is charged at 1.0–1.5 molar equivalents to the growing peptide amino nucleophile in solution-phase couplings, with the exact excess determined by the steric hindrance of the C-terminal amino acid ester. Small-scale syntheses are executed in 50–200 mL Schlenk flasks or 1–5 L jacketed reactors under nitrogen; activation with N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride and 1-hydroxybenzotriazole in dichloromethane at 0–4 °C is followed by coupling for 6–16 h. Purification uses flash chromatography on silica gel for simple protected dipeptides or preparative HPLC for polar research peptides; characterization relies on LC-MS, chiral HPLC, and 1H NMR. Compliance is anchored to ISO 9001:2015 clause 8.5 for production and service provision, while non-clinical research material is produced under GLP principles where the sponsor requires them. Terminal product types include research-grade peptides for enzyme-substrate profiling, MHC-binding assays, and custom peptide libraries. Storage at 2–8 °C under inert gas is required; if ambient relative humidity exceeds 60%, pre-drying under vacuum at 40 °C for 4 h is applied before coupling because residual water deactivates the active ester and reduces coupling conversion by 3–6%.

When Diagnostic Chromogenic Substrates Require N-Terminal Alkoxycarbonyl Protection

Diagnostic chromogenic and fluorogenic peptide substrates built on the p-nitroaniline or 7-amino-4-methylcoumarin reporter platform require an N-terminal alkoxycarbonyl group that remains intact during stepwise chain assembly but is removed quantitatively before the final freeze-drying step, and Cbz-L-alanine provides that protection in solution-phase syntheses. Sequential coupling of Cbz-L-alanine to the growing peptide chain is performed with N,N'-diisopropylcarbodiimide and 1-hydroxybenzotriazole in dimethylformamide at 0–5 °C, using 1.0–1.2 molar equivalents of Cbz-L-alanine per coupling step and a reaction time of 3–8 h. Each intermediate is monitored by thin-layer chromatography and LC-MS; deprotection before the final reporter coupling is achieved with hydrogen bromide in acetic acid at 0–10 °C or catalytic hydrogenolysis, depending on the presence of sulfur-containing side chains. The final substrate is purified by preparative reversed-phase HPLC to ≥98.5% purity and lyophilized to residual trifluoroacetic acid below 0.1%. Compliance for diagnostic substrates follows ISO 13485:2016 clause 7.5 for production and service provision and, for CE-marked finished assays, the EU IVDR 2017/746; material used only for research remains outside the IVDR scope. Terminal product types include chromogenic coagulation substrates, protease assay substrates, and peptide antigens coated in ELISA plates. The operational boundary is the acid lability of the Cbz group relative to acid-labile side-chain protecting groups; when tert-butyl-protected side chains are present, hydrogenolysis is selected over HBr/acetic acid to avoid premature deprotection.

Reduction to Cbz-L-alaninal: A Narrow-Window Intermediate for Peptidomimetic Protease Inhibitors

N-Cbz-L-alanine is converted to Cbz-L-alaninal by activation as its N,O-dimethylhydroxylamine Weinreb amide and subsequent lithium aluminum hydride reduction in anhydrous tetrahydrofuran at -40 °C to -35 °C. The Weinreb amide formation charges Cbz-L-alanine at 1.00–1.05 molar equivalents to N,O-dimethylhydroxylamine hydrochloride, with 1.0–1.1 molar equivalents of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide and 1.0–1.1 molar equivalents of N-methylmorpholine in dichloromethane at 0–5 °C. The reduction uses 1.1–1.3 molar equivalents of lithium aluminum hydride; the reagent is added as a slurry in tetrahydrofuran at such a rate that the internal temperature does not exceed -30 °C. The reaction is quenched with 10% citric acid at -20 °C to avoid over-reduction to Cbz-L-alaninol, which can reach 5–8% if the quenching temperature exceeds -10 °C. The aldehyde is extracted into ethyl acetate and used without further purification in peptidomimetic condensation reactions, because distillation of Cbz-L-alaninal causes partial racemization. Compliance for this intermediate is governed by ICH Q7 Section 8 when the downstream product enters GMP manufacturing, and by REACH for industrial supply; the process is executed in flameproof reactors with oxygen exclusion below 0.5% due to lithium aluminum hydride reactivity. Terminal product types include peptidomimetic protease inhibitor scaffolds, transition-state analog intermediates, and chiral aldehyde building blocks for medicinal chemistry. The operational boundary is strict: the aldehyde must be consumed or stored at -20 °C under argon within 24 h, because dimerization and Cα racemization are observed after this window.